Table 1 .
Characteristics of the study population at the end of tuberculosis treatment
| Characteristics | n=177 (%) |
|---|---|
| Baseline clinical characteristics | |
| Male sex | 101 (57.1) |
| Age, years, median (25th–75th) | 32 (24–45.5) |
| Median duration of symptoms before diagnosis, weeks (25th-75th) | 8 (4–12) |
| Current or past smoking | 35 (19.8) |
| Previous pulmonary tuberculosis | 23 (13) |
| HIV infection | 47 (26.6) |
| Diabetes mellitus | 4 (2.3) |
| Radiological signs | |
| Extension of tuberculosis lesions >4 zones | 52/148 (35.1) |
| Cavitary disease | 81/148 (45.8) |
| Persisting respiratory symptoms | |
| Any respiratory symptoms | 110 (62.1) |
| Cough | 87 (49.2) |
| Expectoration | 62 (35.0) |
| Dyspnoea | 99 (55.9) |
| Spirometry values at the end of treatment | |
| FEV1, %, mean (SD) | 76.3 (19.0) |
| FVC, %, mean (SD) | 74.8 (18.2) |
| FEV1/FVC | 0.86 (0.07) |
| FEF25–75%, %, median (25th–75th) | 74 (56–94.5) |
FEF25–75%, forced expiratory flow between 25% and 75%, FEV1, forced expiratory volume in the first second; FVC, forced vital capacity.